Perceptive Advisors

CEO and Portfolio Manager Joseph Edelman leads the firm alongside CIO and Head of Research Adam Stone. Sam Chawla oversees credit investments, and Michael Altman directs strategy. The firm emphasizes a collaborative, science-driven committee process where MDs and PhDs evaluate opportunities alongside financial professionals.

Perceptive leans on its in-house scientific team — trained technologists, molecular biologists, and clinicians — to identify underappreciated assets before they reach broad auction. By maintaining a singular focus on life sciences, the firm aims to see earlier into academic and clinical pipelines than generalist investors.

Perceptive invests directly across the capital structure — private equity, public equity, venture, and credit — rather than operating as a fund-of-funds. There is no public evidence that the firm allocates to outside GPs.

The firm covers the full life cycle: seed, start-up, early-stage, expansion, late-stage venture, and public companies. Its credit arm additionally provides venture debt, allowing it to back companies from preclinical development through commercial maturity.

Perceptive is exclusively focused on life sciences — biotechnology, pharmaceuticals, diagnostics, medical devices, and healthcare technology. It does not invest in sectors outside healthcare, which is the fundamental constraint for allocators seeking pure-play exposure.

This is not a family office. Perceptive Advisors is an asset manager founded by Joseph Edelman that raises capital from institutional investors. There is no single-family wealth origin.

Perceptive operates its own strategies across venture, public equity, and credit and has not disclosed co-investment programs with external general partners. Allocators negotiating side letters should confirm the absence or presence of co-invest vehicles directly with investor relations.